COVID-19 antibody tests have been the subject of scrutiny since their arrival, but they still represent an important tool in understanding population health. Molecular tests have become the top method of identifying cases of COVID-19. One scientist thinks we should be looking at using a combination of antibody tests, antigen tests, and molecular RNA tests to better understand who has COVID-19 and whether or not they’re actively recovering.
Dr. David Walt is one of the cofounders of genetic sequencing technology giant Illumina and Quanterix, a company that makes technology for detecting biomarkers. He is also co-director of the MGB Center for COVID Innovation at Brigham and Women’s Hospital, in Boston. When COVID-19 struck, he had to close his lab at Harvard University due to the pandemic. He petitioned to reopen, so he and a team could work on a super antibody test that would enable him to better understand immune response in COVID-19 patients. The request was approved.